Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life.
We report on the results of the 12-month follow-up of children aged 14 to 18 months who received primary and booster vaccinations with either a meningococcal-C vaccine conjugated to tetanus toxoid or CRM197. Seroprotection (92.8%) and geometric mean titers/serum bactericidal activity (410.5; 95% CI: 273.4-616.3) were higher in children receiving the meningococcal serogroup C tetanus toxoid conjugate, compared with 61.5% and serum bactericidal antibody geometric mean titer of 45.1 (95% CI: 28.5-71.3) when MenC-CRM197 conjugate was used.
Diez-Domingo
Javier
J
Centro Superior de Investigación en Salud Pública, Valencia, Spain. diez_jav@gva.es
Planelles-Cantarino
M Victoria
MV
Baldo-Torrenti
Jose M
JM
Ubeda-Sansano
Isabel
I
Jubert-Rosich
Angels
A
Puig-Barbera
Joan
J
Gutierrez-Gimeno
M Victoria
MV
D000907:Antibodies, Bacterial / Q000097:blood*; D002675:Child, Preschool; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods*; D007223:Infant; D008589:Meningococcal Infections / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D013745:Tetanus Toxoid / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination / Q000379:methods*
D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines; D011135:Polysaccharides, Bacterial; D013745:Tetanus Toxoid; C052181:meningococcal group C polysaccharide-tetanus toxoid conjugate; C410218:serogroup C meningococcal conjugate vaccine